Kura Oncology Stock Buy Hold or Sell Recommendation
| KURA Stock | USD 20.95 0.13 0.62% |
Given the investment horizon of 90 days and your bold attitude towards risk, our recommendation regarding Kura Oncology is 'Hold'. Macroaxis provides Kura Oncology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding KURA positions.
Check out Kura Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide. In addition, we conduct extensive research on individual companies such as Kura and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Kura |
Execute Kura Oncology Buy or Sell Advice
The Kura recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kura Oncology. Macroaxis does not own or have any residual interests in Kura Oncology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kura Oncology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Kura Oncology Trading Alerts and Improvement Suggestions
| Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73. | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors |
Kura Oncology current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kura analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kura analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Kura Oncology Returns Distribution Density
The distribution of Kura Oncology's historical returns is an attempt to chart the uncertainty of Kura Oncology's future price movements. The chart of the probability distribution of Kura Oncology daily returns describes the distribution of returns around its average expected value. We use Kura Oncology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kura Oncology returns is essential to provide solid investment advice for Kura Oncology.
| Mean Return | 0.12 | Value At Risk | -3.42 | Potential Upside | 4.05 | Standard Deviation | 2.45 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kura Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Kura Stock Institutional Investors
| Shares | Foresite Capital Management Iv, Llc | 2024-06-30 | 1.8 M | Artal Group S A | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.7 M | Assenagon Asset Management Sa | 2024-06-30 | 1.7 M | Commodore Capital Lp | 2024-06-30 | 1.6 M | Franklin Resources Inc | 2024-06-30 | 1.6 M | Tcg Crossover Management, Llc | 2024-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Citadel Advisors Llc | 2024-06-30 | 1 M | Suvretta Capital Management, Llc | 2024-06-30 | 7.1 M | Blackrock Inc | 2024-06-30 | 7 M |
Kura Oncology Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 10.0M | 299.6M | (234.8M) | (38.9M) | (14.5M) | (13.8M) | |
| Free Cash Flow | (54.8M) | (72.0M) | (105.7M) | (110.7M) | (125.0M) | (118.7M) | |
| End Period Cash Flow | 26.1M | 325.7M | 90.9M | 52.0M | 37.3M | 40.3M | |
| Other Non Cash Items | (1.1M) | 410K | 399K | 1.7M | 10.5M | 11.0M | |
| Net Income | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (152.6M) | (145.0M) | |
| Investments | (46.3M) | (97.8M) | (125.7M) | 32.6M | (74.0M) | (77.7M) | |
| Depreciation | (1.1M) | 194K | 558K | 759K | 849K | 891.5K | |
| Change To Netincome | 9.4M | 12.8M | 24.2M | 26.4M | 30.3M | 31.9M |
Kura Oncology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kura Oncology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kura Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kura stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 1.64 | |
σ | Overall volatility | 2.42 | |
Ir | Information ratio | -0.0029 |
Kura Oncology Volatility Alert
Kura Oncology currently demonstrates below-average downside deviation. It has Information Ratio of 0.0 and Jensen Alpha of -0.08. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kura Oncology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kura Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Kura Oncology Fundamentals Vs Peers
Comparing Kura Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kura Oncology's direct or indirect competition across all of the common fundamentals between Kura Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kura Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kura Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kura Oncology to competition |
| Fundamentals | Kura Oncology | Peer Average |
| Return On Equity | -0.39 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Current Valuation | 1.13 B | 16.62 B |
| Shares Outstanding | 76.63 M | 571.82 M |
| Shares Owned By Insiders | 1.07 % | 10.09 % |
| Shares Owned By Institutions | 98.93 % | 39.21 % |
| Number Of Shares Shorted | 10.8 M | 4.71 M |
| Price To Earning | (9.03) X | 28.72 X |
| Price To Book | 3.44 X | 9.51 X |
| EBITDA | (164.96 M) | 3.9 B |
| Net Income | (152.63 M) | 570.98 M |
| Cash And Equivalents | 450.26 M | 2.7 B |
| Cash Per Share | 6.73 X | 5.01 X |
| Total Debt | 17.2 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 25.73 X | 2.16 X |
| Book Value Per Share | 6.10 X | 1.93 K |
| Cash Flow From Operations | (124.82 M) | 971.22 M |
| Short Ratio | 18.70 X | 4.00 X |
| Earnings Per Share | (2.23) X | 3.12 X |
| Target Price | 30.42 | |
| Number Of Employees | 142 | 18.84 K |
| Beta | 0.84 | -0.15 |
| Market Capitalization | 1.61 B | 19.03 B |
| Total Asset | 448.94 M | 29.47 B |
| Retained Earnings | (721.44 M) | 9.33 B |
| Working Capital | 397.22 M | 1.48 B |
| Current Asset | 86.87 M | 9.34 B |
| Current Liabilities | 5.05 M | 7.9 B |
| Net Asset | 448.94 M |
Note: Acquisition by Vasconcelles Michael of 17333 shares of Kura Oncology at 20.88 subject to Rule 16b-3 [view details]
Kura Oncology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kura . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Kura Oncology Buy or Sell Advice
When is the right time to buy or sell Kura Oncology? Buying financial instruments such as Kura Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Kura Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Kura Stock
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Kura Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.23) | Return On Assets (0.25) | Return On Equity (0.39) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.